Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy
Abstract
BACKGROUND: The current study was performed to determine the maximum tolerated dose (MTD), toxicity, and outcome of infusional 5 bromo‐2'‐deoxyuridine (bromodeoxyuridine; BUdR) given with accelerated fractionation whole brain radiation therapy (WBRT) after chemotherapy for the treatment of primary central nervous system lymphoma (PCNSL).METHODS: Twelve patients with untreated and histologically confirmed PCNSL were entered on the study between 1994 and 1996. Chemotherapy was comprised of one course of IDHAP plus high‐dose methotrexate (HD‐MTX). IDHAP is comprised of idarubicin at a dose of 1.5 mg/m2/day × 4 days intravenously by continuous infusion (i.v. CI), dexamethasone at a dose of 40 mg i.v. on Days 1–5, cytosine arabinoside at a dose of 2000 mg/ m2 i.v. on Day 5 after cisplatin, and cisplatin at a dose of 25 mg/m2/day × 4 days i.v. CI. HD‐MTX was given at a dose of 3.5 g/m2 i.v. between Day 10 and Day 14 after IDHAP. BUdR was given as an i.v. CI over 48 hours, 2–3 days prior to WBRT and then weekly during WBRT. Dose escalation started at 1.5 g/m2/day for Cohort 1 with subsequent increments of 0.3 g/m2/day. The WBRT dose was 45 grays (Gy) at a dose of 1.5 Gy twice a day, 5 days per week. Neurocognitive testing was performed before, during, and after treatment.RESULTS: Nine of 12 patients entered on the study received BUdR. One of 3 patients in Cohort 1 developed leukoencephalopathy (LEP), a dose‐limiting toxicity (DLT), within 2 months of the completion of therapy. Therefore, the next cohort received the same dose level. Because no toxicity was observed in Cohort 2, the third cohort received a BUdR dose of 1.8 g /m2/day. Shortly after completing enrollment in Cohort 3, 3 more patients developed LEP, including 2 from Cohort 1 who had received a dose of 1.5 g/m2/day. Thus, DLT occurred at a dose of 1.5 g/m2/day, the starting level in the current study. As a result, the trial was stopped. Eight of 12 patients achieved a complete response, 3 achieved a partial response, and 1 patient died before response assessment.CONCLUSIONS: Hyperfractionated WBRT with concurrent BUdR after chemotherapy was found to result in modest disease control but has unacceptable neurotoxicity. Cancer 2003;98:1021–8. © 2003 American Cancer Society.DOI 10.1002/cncr.11627Keywords
This publication has 31 references indexed in Scilit:
- Primary central nervous system lymphomaJournal of Neurology, Neurosurgery & Psychiatry, 1999
- Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest ReliabilityThe Clinical Neuropsychologist, 1998
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Primary Malignant Lymphoma of the Brain: A report of 24 cases from the Norwegian Radium HospitalActa Oncologica, 1992
- Prognostic factors in the diagnosis and treatment of primary central nervous system lymphomaCancer, 1989
- Primary malignant lymphoma of the central nervous systemJournal of Neurosurgery, 1986
- Radiosensitization of Malignant Brain Tumours with Bromouridine (Thymidine Analogue)Acta Radiologica: Therapy, Physics, Biology, 1969
- Radiosensitization of Brain Tumor Cells with a Thymidine Analogue (Bromouridine)Journal of Neurosurgery, 1968
- Experimental and Clinical Studies of Radiosensitizers in Brain Tumors, with Special Reference to BUdR-Antimetabolite Continuous Regional Infusion-Radiation Therapy (BAR therapy)Neurologia medico-chirurgica, 1965
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958